Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)

Completed · Not applicable

Conditions studied: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Acquired Aplastic Anemia, Sickle Cell Disease

In brief

The purpose of this study is to determine if a search strategy of searching for an HLA-matched unrelated donor for allogeneic transplantation if possible then an alternative donor if an HLA-matched unrelated donor is not available versus proceeding directly to an alternative donor transplant will result in better survival for allogeneic transplant recipients within 2 years after study enrollment.

Key facts

Study ID

NCT03904134

Run by

Center for International Blood and Marrow Transplant Research

People needed

1753

Starts

2019-06-14

Expected to finish

2025-01-06

Last updated by the study team

2026-01-05

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients fulfilling the inclusion criteria will be eligible for enrollment in this study. Of those who consent, only patients who lack a suitable HLA-identical or 1 allele or antigen mismatched related donors are evaluable. Patients with an HLA-identical sibling or 1 allele or antigen mismatched family member donor are evaluable as long as the center deems the family member donor as unsuitable for other reasons. Patients may co-enroll with other interventional or observational studies.
• Patients of all ages with AML, ALL, MDS, NHL, HL, AA, or SCD are eligible.
• Any planned conditioning regimen and GVHD prophylaxis approach is eligible.
• Patients must be considered suitable allogeneic transplant candidates at the time of enrollment based on medical history, physical examination, and available laboratory tests. Specific testing for organ function is not required for eligibility but, if available, these tests should be used by the treating physician to judge transplant suitability.
• Patient and physician must intend to proceed with allogeneic HCT within the next 6 months if a suitable donor is identified.
• Center plans to follow the algorithm for alternative donor identification: (a) for subjects who are Very Likely to find a MUD, attempt to identify a matched unrelated donor; (b) for a subjects who are Very Unlikely to find a MUD, proceed expeditiously to a haploidentical, cord blood or mismatched unrelated donor.
• Signed informed consent, and assent if applicable. Consent may be signed prior to completion of family typing but patients will only be considered evaluable upon confirmation that there is no suitable HLA-identical or 1 allele or antigen mismatched related donor available.

You may not qualify if…

• Prior allogeneic HCT (prior autologous transplant is allowed)
• Previous formal unrelated donor search

Where it is running

• University of California, San Diego Medical Center — La Jolla, California, United States
• Children's Hospital Los Angeles — Los Angeles, California, United States
• Stanford Hospitals and Clinics — Stanford, California, United States
• Children's National Medical Center — Washington D.C., District of Columbia, United States
• University of Florida — Gainesville, Florida, United States
• University of Miami — Miami, Florida, United States
• Memorial Healthcare System — Pembroke Pines, Florida, United States
• H. Lee Moffitt Cancer Center — Tampa, Florida, United States
• Children's Healthcare of Atlanta — Atlanta, Georgia, United States
• Emory University — Atlanta, Georgia, United States
• Northside Hospital — Atlanta, Georgia, United States
• Loyola University — Maywood, Illinois, United States
• Indiana University — Indianapolis, Indiana, United States
• University of Maryland — Baltimore, Maryland, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• University of Michigan — Ann Arbor, Michigan, United States
• Karmanos Cancer Institute — Detroit, Michigan, United States
• University of Minnesota — Minneapolis, Minnesota, United States
• Mayo Clinic Rochester — Rochester, Minnesota, United States
• University of Mississippi — Jackson, Mississippi, United States
• Children's Mercy Hospital — Kansas City, Missouri, United States
• St. Louis Children's Hospital — St Louis, Missouri, United States
• Washington University in St. Louis — St Louis, Missouri, United States
• University of Nebraska Medical Center - Adults — Omaha, Nebraska, United States
• City of Hope — Duarte, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.